Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,370 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05965531RecruitingPhase 2
TAS-102 plus radiation before surgery for rectal cancer
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Guangzhou, GuangdongAges 18–70 - NCT05980715RecruitingPhase 3
Comparing immunotherapy to radiation after successful treatment for head and neck cancer
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
Guangzhou, GuangdongAges 18–65 - NCT05984485RecruitingPhase 3
Surgery vs chemo before surgery for low-risk rectal cancer
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05989828RecruitingPhase 1
Engineered immune cells for advanced triple-negative breast cancer
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT06010862RecruitingPhase 1
CAR-T therapy for CEA-positive advanced cancers
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
Nanchang, JiangxiAges 18 years+ - NCT06014372RecruitingPhase 2
Envafolimab before surgery for advanced rectal cancer
This trial tests envalolimab (an immunotherapy) alone or with chemo (CAPEOX) before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06017583RecruitingPhase 3
Chemo plus immunotherapy and targeted radiation for advanced rectal cancer
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
Nanning, GuangxiAges 18–70 - NCT06019468RecruitingPhase 2
Pre-surgery Treatment for Advanced Thymic Cancer
This trial tests a new treatment given before surgery for people with advanced thymic carcinoma. It aims to shrink the tumor and make surgery more effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06021626RecruitingPhase 1
Study of CRD3874-SI for advanced solid tumors
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Basking Ridge, New JerseyAges 18 years+ - NCT06022861RecruitingPhase 3
Study of LY01015 vs Opdivo with chemo for advanced esophageal cancer
This trial tests a new drug, LY01015, against Opdivo when both are given with chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. It aims to see if LY01015 works as well as Opdivo and has similar safety.
GuangzhouAges 18–75 - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06026943Recruiting
Alpha radiation therapy for locally advanced pancreatic cancer
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
VeronaAges 18–120 - NCT06044623RecruitingPhase 3
Tailoring cancer pill dosing for older adults with breast cancer
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
HelsinkiAges 70 years+ - NCT06054906RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
ShanghaiAges 18 years+ - NCT06055816RecruitingPhase 2
Gemcitabine plus two targeted drugs for older adults with nasopharyngeal cancer
This trial tests a combination of three drugs—chemotherapy (gemcitabine), a blood-vessel blocker (Endostar), and an immunotherapy (Envafolimab)—for older adults with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard care for patients aged 65 and up.
Hangzhou, ZhejiangAges 65 years+ - NCT06074692RecruitingPhase 2
PARP inhibitor, SBRT, and immunotherapy for advanced sarcoma
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 10–70 - NCT06083103Recruiting
PET/MRI for advanced cervical cancer
This trial uses a combined PET and MRI scan to see if it can better identify the spread of cervical cancer before treatment. It may help guide more personalized care.
StrasbourgAges 18 years+ - NCT06093438RecruitingPhase 1/Phase 2
Toripalimab plus chemo for advanced cervical cancer
This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06105684RecruitingPhase 2
Low-dose capecitabine for advanced breast cancer
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
Birmingham, AlabamaAges 60 years+ - NCT06125080RecruitingPhase 2
Study of utidelone plus tirelizumab and bevacizumab for advanced triple-negative breast cancer
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
Wuhan, HubeiAges 18–70 - NCT06128148RecruitingPhase 1
Study of JYP0322 for ROS1 fusion-positive solid tumors
This trial tests an experimental drug called JYP0322 for people with advanced solid tumors that have a specific genetic change called a ROS1 fusion. The goal is to see if the drug is safe and effective against these tumors.
Guangzhou, GuangdongAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,370 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.